• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

How will COVID-19 impact value-based models?

Author(s):

COVID-19 has left providers with fewer in-office visits, more telehealth appointments and, for many, reduced revenue.

But even as doctors struggle with the day-to-day challenges of practicing under radically new circumstances, some health care policy makers, academics and payers are asking another question: What do the changes caused by the pandemic mean for accountable care organizations (ACOs) and other value-based care models, under which doctors and practices are rewarded for keeping patients healthy while holding costs down?

Read from experts who spoke to our sister publication, Medical Economics on this topic.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.